ClinicalTrials.gg
CompletedNCT01323634Updated Nov 8, 2017Results posted

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg and Fluticasone Propionate 250mcg/ salmeterol 50mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 51 sites in 6 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-11-08.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
519
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.

Enrollment
9th of 25
519 · median 229
Started
2011
with 3 others
Phase 3
7 of 25
none open now
Registered
2nd of 25
by date
Lead sponsor
21 of 25
GlaxoSmithKline

Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 9th largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 2nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with COPD.

Read the detailed description

This is a randomized, double-blind, double-dummy, multi-centre parallel group study. Subjects who meet the eligibility criteria at Screening and meet the randomization criteria at the end of a 2-week Run-In period will enter a 12-week treatment period. There will be a 7-day Follow-up period after the treatment period.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written
  • Male or females ≥ 40 years of age
  • Established clinical history of by ATS/ERS definition
  • Females are eligible to enter and participate if of non-, or if of child bearing potential, has a negative serum pregnancy test at screening, and agrees to one of the acceptable methods listed in protocol, used consistently and correctly
  • Former or current smoker > 10 pack years
  • Post-albuterol spirometry criteria: /FVC ratio ≤ 0.70 and FEV1 ≤ 70% of predicted normal (NHANES III)

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of asthma
  • Subjects with other respiratory disorders including active tuberculosis, α1-antitrypsin deficiency, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
  • Lung volume reduction surgery within previous 12 months
  • abnormalities not due to by chest x-ray
  • Hospitalized for poorly controlled COPD within 12 weeks of Screening
  • Poorly controlled COPD 6 weeks prior to Screening, defined as acute worsening of COPD that is managed by the subject with or antibiotics or that requires treatment prescribed by a physician
  • Lower respiratory infection requiring antibiotics 6 weeks prior to Screening
  • Uncontrolled or clinically significant (in opinion of PI) cardiovascular, hypertension, neurological, psychiatric, renal, hepatic, immunological, endocrine, peptic ulcer disease, or hematological abnormalities
  • Carcinoma not in complete remission for at least 5 years
  • Subjects with history of to study medications (e.g., beta-agonists, corticosteroid) or components of inhalation powder (e.g., lactose, magnesium stearate)
  • Subjects with history of severe milk protein allergy that, in opinion of study physician, contraindicates subject's participation
  • Known/suspected history of alcohol or drug abuse in the last 2 years
  • Women who are pregnant or lactating or plan to become pregnant
  • Subjects medically unable to withhold albuterol and/or ipratropium 4 hours prior to spirometry testing at each study visit
  • Use of certain medications such as bronchodilators and corticosteroids for the protocol-specific times prior to Visit 1 (the Investigator will discuss the specific medications)
  • Long Term Oxygen Therapy (LTOT) or nocturnal oxygen therapy >12 hours a day
  • Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening or during the study
  • Non-compliance or inability to comply with study procedures or scheduled visits
  • Affiliation with investigator site
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
519 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate / GW642444 (vilanterol)

    Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)

    Drug: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg

  • Active comparator
    Fluticasone Propionate / salmeterol

    Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)

    Drug: Fluticasone Propionate 250mcg/ salmeterol 50mcg

Interventions

  • DrugFluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg

    Drug page: Fluticasone furoate

    inhalation powder

  • DrugFluticasone Propionate 250mcg/ salmeterol 50mcg

    Drug page: Fluticasone

    inhalation powder

06

What researchers measure

Primary outcomes

  1. Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84

    Pulmonary function was measured by forced expiratory volume in one second (FEV1). The weighted mean was calculated from the pre-dose FEV1 and the post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 4, 6, 8, 12, 13, 14, 16, 20, and 24 hours on Treatment Day 84. Baseline trough FEV1 was the mean of the two assessments made 30 and 5 minutes pre-dose on Treatment Day 1. Change from Baseline was calculated as the average of the Day 84 values minus the Baseline value.

    Time frame: Baseline (Day 1) and Day 84

Secondary outcomes

  1. Time to Onset on Treatment Day 1

    Time to onset on Treatment Day 1 is defined as the time to an increase of 100 milliliters (mL) from Baseline in FEV1. Time of onset was calculated over 0 to 4 hours (5 min, 30 min, 60 min, 120 min, and 240 min) post-dose.

    Time frame: Day 1

07

Results

Posted Jul 30, 2013

Participant flow

2-week Run-in Period
Participant flow — 2-week Run-in Period
MilestonePlacebo + SalbutamolFSC 250/50 µg BIDFF/VI 100/25 µg QD
Started73300
Completed52100
Not completed21200
Withdrew: Inclusion/exclusion criteria not met12500
Withdrew: Continuation criteria not met7300
Withdrew: Withdrawal by subject700
Withdrew: Physician decision500
Withdrew: Protocol violation100
Withdrew: Adverse event100
Double-Blind (DB) Treatment Period
Participant flow — Double-Blind (DB) Treatment Period
MilestonePlacebo + SalbutamolFSC 250/50 µg BIDFF/VI 100/25 µg QD
Started0260261
Completed0235239
Not completed02522
Withdrew: Adverse event084
Withdrew: Lack of efficacy002
Withdrew: Protocol violation067
Withdrew: Lost to follow-up011
Withdrew: Physician decision023
Withdrew: Withdrawal by subject074
Withdrew: Did not receive db study medication011

Outcome measures

PrimaryChange From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84

Pulmonary function was measured by forced expiratory volume in one second (FEV1). The weighted mean was calculated from the pre-dose FEV1 and the post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 4, 6, 8, 12, 13, 14, 16, 20, and 24 hours on Treatment Day 84. Baseline trough FEV1 was the mean of the two assessments made 30 and 5 minutes pre-dose on Treatment Day 1. Change from Baseline was calculated as the average of the Day 84 values minus the Baseline value.

Time frame:
Baseline (Day 1) and Day 84
Reported as:
Least squares mean · Liters
Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84
LitersFSC 250/50 µg BIDFF/VI 100/25 µg QD
Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 840.094 ± 0.01580.174 ± 0.0153
Statistical analysis
  • FSC 250/50 µg BID vs FF/VI 100/25 µg QD · ANCOVA · p = <0.001 · Least square mean difference: 0.080 · 95% CI 0.037 to 0.124
SecondaryTime to Onset on Treatment Day 1

Time to onset on Treatment Day 1 is defined as the time to an increase of 100 milliliters (mL) from Baseline in FEV1. Time of onset was calculated over 0 to 4 hours (5 min, 30 min, 60 min, 120 min, and 240 min) post-dose.

Time frame:
Day 1
Reported as:
Median · Minutes
Time to Onset on Treatment Day 1
MinutesFSC 250/50 µg BIDFF/VI 100/25 µg QD
Time to Onset on Treatment Day 130 (5 to 240)15 (5 to 240)

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events were collected from Baseline to the end of the study (up to 12 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FSC 250/50 µg BID—8/259 (3.1%)18/259 (6.9%)
FF/VI 100/25 µg QD—3/260 (1.2%)23/260 (8.8%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventFSC 250/50 µg BIDFF/VI 100/25 µg QD
Chronic onstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders3/2590/260
EpistaxisRespiratory, thoracic and mediastinal disorders1/2590/260
Atrial fibrillationCardiac disorders1/2591/260
Cardiac failure congestiveCardiac disorders1/2590/260
Cardio-respiratory arrestCardiac disorders1/2590/260
BronchitisInfections and infestations1/2590/260
Rib fractureInjury, poisoning and procedural complications1/2590/260
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/2591/260
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2591/260
CholecystitisHepatobiliary disorders0/2591/260
Most frequent other events
Most frequent other events
EventFSC 250/50 µg BIDFF/VI 100/25 µg QD
HeadacheNervous system disorders11/25916/260
NasopharyngitisInfections and infestations7/2598/260

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FSC 250/50 µg BIDFF/VI 100/25 µg QDTotal
Mean61.2 ± 8.3261.1 ± 7.9261.2 ± 8.11
Sex: Female, Male
Sex: Female, Male(Participants)FSC 250/50 µg BIDFF/VI 100/25 µg QDTotal
Female9096186
Male169164333
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FSC 250/50 µg BIDFF/VI 100/25 µg QDTotal
African American/ African Heritage9514
American Indian or Alaska Native011
White/Caucasian/European Heritage250254504
08

Study locations

51 sites
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Orlando, Florida 32822, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Madisonville, Kentucky 42431, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63141, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Columbus, Ohio 43215, United States
  • GSK Investigational Site
    Easley, South Carolina 29640, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Union, South Carolina 29379, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    Benesov, 256 30, Czechia
  • GSK Investigational Site
    Blansko, 678 31, Czechia
  • GSK Investigational Site
    Kromeriz, 767 55, Czechia
  • GSK Investigational Site
    Kyjov, 697 33, Czechia
  • GSK Investigational Site
    Melnik, 276 01, Czechia
  • GSK Investigational Site
    Novy Jicin, 741 01, Czechia
  • GSK Investigational Site
    Rokycany, 337 01, Czechia
  • GSK Investigational Site
    Trebic, 674 01, Czechia
  • GSK Investigational Site
    Frankfurt am Main, Hessen 60596, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Wiesbaden, Hessen 65183, Germany
  • GSK Investigational Site
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 14057, Germany
  • GSK Investigational Site
    Dzialdowo, 13-200, Poland
  • GSK Investigational Site
    Elblag, 82-300, Poland
  • GSK Investigational Site
    Inowrocław, 88-100, Poland
  • GSK Investigational Site
    Katowice, 40-018, Poland
  • GSK Investigational Site
    Krakow, 31-159, Poland
  • GSK Investigational Site
    Poznan, 60-214, Poland
  • GSK Investigational Site
    Wroclaw, 54-239, Poland
  • GSK Investigational Site
    Brasov, 500112, Romania
  • GSK Investigational Site
    Brasov, 500283, Romania
  • GSK Investigational Site
    Bucharest, 011794, Romania
  • GSK Investigational Site
    Bucharest, 030317, Romania
  • GSK Investigational Site
    Bucharest, 050159, Romania
  • GSK Investigational Site
    Bucuresti, 70000, Romania
  • GSK Investigational Site
    Cluj Napoca, 400371, Romania
  • GSK Investigational Site
    Iasi, 700115, Romania
  • GSK Investigational Site
    Suceava, 720284, Romania
  • GSK Investigational Site
    Timisoara, 300310, Romania
  • GSK Investigational Site
    Barnaul, 656024, Russian Federation
  • GSK Investigational Site
    Barnaul, 656038, Russian Federation
  • GSK Investigational Site
    Kaluga, 248007, Russian Federation
  • GSK Investigational Site
    Kemerovo, 650002, Russian Federation
  • GSK Investigational Site
    Kursk, 305035, Russian Federation
  • GSK Investigational Site
    Moscow, 125367, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 194291, Russian Federation
09

References and documents

Publications

  • Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Respir Med. 2014 Aug;108(8):1171-9. doi: 10.1016/j.rmed.2014.05.008. Epub 2014 Jun 19. PubMed 24998880 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Dec 2011, 8 months.

Results were first posted in Jul 2013, 1 year 7 months after primary completion. A results delay was requested in Jun 2012.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 8 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2011
First posted
Mar 25, 2011
StartActual
Mar 18, 2011
Primary completionActual
Dec 14, 2011
CompletionActual
Dec 14, 2011
Results delay requested
Jun 14, 2012
Results first posted
Jul 30, 2013
Last update
Nov 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01323634
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 25, 2011
Start date
Mar 18, 2011
Primary completion
Dec 14, 2011
Completion
Dec 14, 2011
Results posted
Jul 30, 2013
Last update
Nov 8, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion